Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert A Hauser

Showing results (141-150 of 266) with videos related to

Pageof 27
Sort By:
Movement Disorders : Official Journal of the Movement Disorder Society|July 20, 2016
Sublingual apomorphine (APL-130277) for the acute conversion of OFF to ON in Parkinson's diseaseRobert A Hauser, C Warren Olanow, Bruce Dzyngel, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|December 17, 2008
Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's diseaseRobert A Hauser, Mark F Lew, Howard I Hurtig, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|December 17, 2013
Double-blind study of the actively transported levodopa prodrug XP21279 in Parkinson's diseasePeter A LeWitt, F Jacob Huff, Robert A Hauser, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|December 7, 2006
A double-blind placebo-controlled trial of zonisamide (zonegran) in the treatment of essential tremorTheresa A Zesiewicz, Christopher L Ward, Robert A Hauser, et al.
Neurology|September 10, 2013
Randomized trial of cognitive speed of processing training in Parkinson diseaseJerri D Edwards, Robert A Hauser, Melissa L O'Connor, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|July 20, 2016
Long-term effects of rasagiline and the natural history of treated Parkinson's diseaseOlivier Rascol, Robert A Hauser, Fabrizio Stocchi, et al.
Clinical Trials (London, England)|August 31, 2016
Communicating with participants during the conduct of multi-center clinical trialsErika F Augustine, E Ray Dorsey, Robert A Hauser, et al.
The International Journal of Neuroscience|January 19, 2018
A 500 U/2 mL dilution of abobotulinumtoxinA vs. placebo: randomized study in cervical dystoniaMark F Lew, Allison Brashear, Khashayar Dashtipour, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|September 9, 2015
NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double-blind, placebo-controlled studyChristopher F O'Brien, Roland Jimenez, Robert A Hauser, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|August 10, 2004
Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patientsMatthew B Stern, Kenneth L Marek, Joseph Friedman, et al.
Pageof 27

Showing results (141-150 of 266) with videos related to

Sort By:
Pageof 27
Movement Disorders : Official Journal of the Movement Disorder Society|July 20, 2016
Sublingual apomorphine (APL-130277) for the acute conversion of OFF to ON in Parkinson's diseaseRobert A Hauser, C Warren Olanow, Bruce Dzyngel, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|December 17, 2008
Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's diseaseRobert A Hauser, Mark F Lew, Howard I Hurtig, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|December 17, 2013
Double-blind study of the actively transported levodopa prodrug XP21279 in Parkinson's diseasePeter A LeWitt, F Jacob Huff, Robert A Hauser, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|December 7, 2006
A double-blind placebo-controlled trial of zonisamide (zonegran) in the treatment of essential tremorTheresa A Zesiewicz, Christopher L Ward, Robert A Hauser, et al.
Neurology|September 10, 2013
Randomized trial of cognitive speed of processing training in Parkinson diseaseJerri D Edwards, Robert A Hauser, Melissa L O'Connor, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|July 20, 2016
Long-term effects of rasagiline and the natural history of treated Parkinson's diseaseOlivier Rascol, Robert A Hauser, Fabrizio Stocchi, et al.
Clinical Trials (London, England)|August 31, 2016
Communicating with participants during the conduct of multi-center clinical trialsErika F Augustine, E Ray Dorsey, Robert A Hauser, et al.
The International Journal of Neuroscience|January 19, 2018
A 500 U/2 mL dilution of abobotulinumtoxinA vs. placebo: randomized study in cervical dystoniaMark F Lew, Allison Brashear, Khashayar Dashtipour, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|September 9, 2015
NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double-blind, placebo-controlled studyChristopher F O'Brien, Roland Jimenez, Robert A Hauser, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|August 10, 2004
Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patientsMatthew B Stern, Kenneth L Marek, Joseph Friedman, et al.
Pageof 27